Cispa-50

Cisplatin

Treatment of advanced or metastasised testicular cancer, ovarian cancer, bladder carcinoma, squamous cell carcinoma of the head & neck, non-small cell lung carcinoma, small cell lung carcinoma.

Adult & childn Monotherapy 50-120 mg/m² as single dose every 3-4 wk; 15-20 mg/m²/day for 5 days every 3-4 wk. Combination chemotherapy 20 mg/m² or more once every 3 to 4 wk. Treatment of cervical cancer in combination w/ radiotherapy 40 mg/m² wkly for 6 wk.

Hypersensitivity. Pre-existing renal impairment, dehydrated condition, myelosuppression, pre-existing hearing impairment, neuropathy (caused by cisplatin). In combination w/ live vaccines including Yellow fever vaccine; phenytoin in prophylactic use. Lactation.

Avoid all Al containing IV sets, needles, catheters & syringe. Do not mix w/ other drugs or additives. Nephrotoxicity. If vigorous hydration is insufficient to maintain adequate urinary output, an osmotic diuretic may be administered (eg, mannitol). Patients w/ peripheral neuropathy not caused by cisplatin. Decreased ability to hear conversational tones may occur. Monitor audiometry prior to initiation of therapy & prior to subsequent doses. Vestibular toxicity. Discontinue if hypersensitivity reactions occur. Cross reactions w/ platinum compd. Regularly monitor haematological formula & hepatic function. Carcinogenic potential. Monitor the infusion site for possible infiltration during drug administration. Close supervision must also be carried out w/ regard to ototoxicity, myelodepression & anaphylactic reactions. Skin lesions in the event of accidental exposure to the product. Acute bacterial or viral infections. Male & female patients have to use effective contraception during & for at least 6 mth after the treatment. Do not use during pregnancy.

Bone marrow failure, thrombocytopenia, leukopenia, anaemia; hyponatraemia; hyperuricaemia. Sepsis; arrhythmia, bradycardia, tachycardia; phlebitis at inj site; dyspnoea, pneumonia, resp failure.

May boost myelosuppressive effects w/ myelosuppressives or radiation. Intensified nephrotoxicity w/ furosemide, hydralazine, diazoxide & propranolol. May potentiate toxic effect w/ nephrotoxic (eg, cephalosporins, aminoglycosides or amphotericin B or contrast media) or ototoxic (eg, aminoglycosides) drugs. Reduced renal elimination w/ cytostatic agents eg, bleomycin & methotrexate. May enhance renal toxicity of ifosfamide. Reduced blood lithium values w/ bleomycin & etoposide. Increased serum uric acid w/ allopurinol, colchicine, probenecid or sulfinpyrazone. More severe neurotoxic effects w/ docetaxel. May diminish effectiveness w/ chelating agents eg, penicillamine. Risk of lymphoproliferation w/ ciclosporin. May potentiate toxic effect on auditory function w/ ototoxic drugs (eg, aminoglycosides, loop diuretics). May increase hearing loss w/ ifosfamide. Risk of fatal systemic vaccinal disease w/ Yellow fever vaccine. Simultaneous use of oral anticoagulants (regularly check the INR). May mask ototoxicity symptoms w/ antihistamines, buclizine, loxapine, meclozine, phenothiazines, thioxanthenes or trimethobenzamides. May reduce absorption of phenytoin. May unfavourably affect response time w/ pyridoxine & altretamine (hexamethylamine). Intensified neurotoxicity of paclitaxel.

Cytotoxic Chemotherapy

L01XA01 - cisplatin ; Belongs to the class of platinum-containing antineoplastic agents. Used in the treatment of cancer.

Rx